These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7979296)

  • 1. Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323.
    Erickson-Viitanen S; Klabe RM; Cawood PG; O'Neal PL; Meek JL
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1628-34. PubMed ID: 7979296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein.
    Rayner MM; Cordova BC; Meade RP; Aldrich PE; Jadhav PK; Ru Y; Lam PY
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1635-40. PubMed ID: 7979297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
    Hodge CN; Aldrich PE; Bacheler LT; Chang CH; Eyermann CJ; Garber S; Grubb M; Jackson DA; Jadhav PK; Korant B; Lam PY; Maurin MB; Meek JL; Otto MJ; Rayner MM; Reid C; Sharpe TR; Shum L; Winslow DL; Erickson-Viitanen S
    Chem Biol; 1996 Apr; 3(4):301-14. PubMed ID: 8807858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
    Rodgers JD; Lam PY; Johnson BL; Wang H; Li R; Ru Y; Ko SS; Seitz SP; Trainor GL; Anderson PS; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Wright MR; Chang CH; Erickson-Viitanen S
    Chem Biol; 1998 Oct; 5(10):597-608. PubMed ID: 9818151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors.
    Nugiel DA; Jacobs K; Kaltenbach RF; Worley T; Patel M; Meyer DT; Jadhav PK; De Lucca GV; Smyser TE; Klabe RM; Bacheler LT; Rayner MM; Seitz SP
    J Med Chem; 1996 May; 39(11):2156-69. PubMed ID: 8667359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs.
    Nillroth U; Vrang L; Markgren PO; Hultén J; Hallberg A; Danielson UH
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2383-8. PubMed ID: 9371337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
    Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
    J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
    Patel M; Bacheler LT; Rayner MM; Cordova BC; Klabe RM; Erickson-Viitanen S; Seitz SP
    Bioorg Med Chem Lett; 1998 Apr; 8(7):823-8. PubMed ID: 9871548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.
    Wu X; Liu H; Xiao H; Conway JA; Kappes JC
    J Virol; 1996 Jun; 70(6):3378-84. PubMed ID: 8648668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic binding of inhibitors to the protease from HIV type 1.
    Asante-Appiah E; Chan WW
    Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):113-7. PubMed ID: 8670094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro.
    McPhee F; Caldera PS; Bemis GW; McDonagh AF; Kuntz ID; Craik CS
    Biochem J; 1996 Dec; 320 ( Pt 2)(Pt 2):681-6. PubMed ID: 8973584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
    Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease.
    Grant SK; Deckman IC; Minnich MD; Culp J; Franklin S; Dreyer GB; Tomaszek TA; Debouck C; Meek TD
    Biochemistry; 1991 Aug; 30(34):8424-34. PubMed ID: 1883829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
    Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
    J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular recognition of cyclic urea HIV-1 protease inhibitors.
    Ala PJ; DeLoskey RJ; Huston EE; Jadhav PK; Lam PY; Eyermann CJ; Hodge CN; Schadt MC; Lewandowski FA; Weber PC; McCabe DD; Duke JL; Chang CH
    J Biol Chem; 1998 May; 273(20):12325-31. PubMed ID: 9575185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical synthesis of a biotinylated derivative of the simian immunodeficiency virus protease. Purification by avidin affinity chromatography and autocatalytic activation.
    Tomasselli AG; Bannow CA; Deibel MR; Hui JO; Zurcher-Neely HA; Reardon IM; Smith CW; Heinrikson RL
    J Biol Chem; 1992 May; 267(15):10232-7. PubMed ID: 1587812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.
    Fehér A; Weber IT; Bagossi P; Boross P; Mahalingam B; Louis JM; Copeland TD; Torshin IY; Harrison RW; Tözsér J
    Eur J Biochem; 2002 Aug; 269(16):4114-20. PubMed ID: 12180988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.